Recommended clinical trial end points for dialysis catheters

Michael Allon, Deborah J. Brouwer-Maier, Kenneth Abreo, Kevin M. Baskin, Kay Bregel, Deepa H. Chand, Andrea M. Easom, Leonard Mermel, Michele H. Mokrzycki, Priti R. Patel, Prabir Roy-Chaudhury, Surendra Shenoy, Rudolph P. Valentini, Haimanot Wasse

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Central venous catheters are used frequently in patients on hemodialysis as a bridge to a permanent vascular access. They are prone to frequent complications, including catheter-related bloodstream infection, catheter dysfunction, and central vein obstruction. There is a compelling need to develop new drugs or devices to prevent central venous catheter complications. We convened a multidisciplinary panel of experts to propose standardized definitions of catheter end points to guide the design of future clinical trials seeking approval from the Food and Drug Administration. Our workgroup suggests diagnosing catheter-related bloodstream infection in catheter-dependent patients on hemodialysis with a clinical suspicion of infection (fever, rigors, altered mental status, or unexplained hypotension), blood cultures growing the same organism from the catheter hub and a peripheral vein (or the dialysis bloodline), and absence of evidence for an alternative source of infection. Catheter dysfunction is defined as the inability of a central venous catheter to (1) complete a single dialysis session without triggering recurrent pressure alarms or (2) reproducibly deliver a mean dialysis blood flow of >300 ml/min (with arterial and venous pressures being within the hemodialysis unit parameters) on two consecutive dialysis sessions or provide a Kt/V≥1.2 in 4 hours or less. Catheter dysfunction is defined only if it persists, despite attempts to reposition the patient, reverse the arterial and venous lines, or forcefully flush the catheter. Central vein obstruction is suspected in patients with >70% stenosis of a central vein by contrast venography or the equivalent, ipsilateral upper extremity edema, and an existing or prior history of a central venous catheter. There is some uncertainty about the specific criteria for these diagnoses, and the workgroup has also proposed future high-priority studies to resolve these questions.

Original languageEnglish (US)
Pages (from-to)495-500
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 7 2018

    Fingerprint

Keywords

  • Bacteremia
  • Blood Culture
  • Catheter-Related Infections
  • Central vein
  • Central Venous Catheters
  • Chills
  • Constriction
  • Dialysis access
  • Edema
  • Humans
  • Hypotension
  • Pathologic
  • Phlebography
  • Renal dialysis
  • Uncertainty
  • United States
  • United States Food and Drug Administration
  • Vascular access
  • Veins
  • Venous Pressure

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Allon, M., Brouwer-Maier, D. J., Abreo, K., Baskin, K. M., Bregel, K., Chand, D. H., ... Wasse, H. (2018). Recommended clinical trial end points for dialysis catheters. Clinical Journal of the American Society of Nephrology, 13(3), 495-500. https://doi.org/10.2215/CJN.12011116